Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO - CNBC

Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO - CNBC
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss - CNBC
4 stocks to watch on Friday: PM, PFE, MSTR, HIMS
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
167.86BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US7170811035
CUSIP
717081103
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
42.07
PEG Ratio
8.97
Book Value
15.61
Dividend Share
2.15
Dividend Yield
7.32%
Earnings Share
0.7
Wall Street Target Price
30.22
EPS Estimate Current Year
3.05
EPS Estimate Next Year
2.95
EPS Estimate Current Quarter
0.7349
EPS Estimate Next Quarter
0.7061
Most Recent Quarter
-
Revenue TTM
63,623,999,488
Gross Profit TTM
47,652,999,168
EBITDA
24,937,000,960
Profit Margin
6.34%
Return On Assets TTM
5.59%
Return On Equity TTM
4.47%
Revenue Per Share TTM
11.173
Qtly Revenue Growth YOY
-0.40%
Diluted Eps TTM
0.7
Qtly Earnings Growth YOY
-9.70%
Trailing PE
42.07
Forward PE
9
Price Sales TTM
2.6383
Price Book MRQ
1.8803
Enterprise Value Revenue
3
Enterprise Value EBITDA
16
496.93
3.59%286.40
1.05%1443.42
0.58%184.91
0.25%160.15
0.10%485.00
0.04%294.82
0.01%162.12
0.00%60.57
0.00%146.60
-0.25%Curated watchlists where PFE is featured.